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Abstract 
Background:  Health insurance schemes are formed in both developed and developing countries as a result of 
the existing challenges in the health care financing system stemming from uneven social and economic 
distribution. This study was conducted to find out the perception and experience of providers and clients in both 
public and private facilities on NHIS medicines list. Methods: A quantitative descriptive study was conducted  
through systematic random sampling to recruit 455 participants from both Nimo Pharmacy (Private facility) and 
Komfo Anokye Teaching Hospital (Public facility). Results: Majority of the clients were aware of NHIS 
medicines or generics medicines and branded medicines. However, most of them preferred NHIS medicines to 
branded medicines. The reasons provided for opting for NHI medicines were effective (p-value= 0.088) 
affordability (p-value= 0.001) availability (p-value= 0.001), safety (p-value=0.645) and less side effects (p-
value=0.012). Again, factors that might influence providers’ prescription patterns of NHIS medicines list were; 
provider’s personal preference, clients’ preference, confidence in the generic company and advertisement by 
generic company.Conclusion: A database of all generic medicines should be created as well as their inventory 
level be maintained for every accredited NHIS facility by the Ministry of Health and National Health Insurance 
Authority. This will make information on NHIS medicines readily available and clients can easily be directed to 
another accredited facility by the provider to access NHIS medicines if they are not available at the visiting 
facility.  
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1. Introduction 
There are several health care systems in the world, each with unique characteristics to address specific health 
needs of individual countries. The health insurance scheme was however formed in both developed and 
developing countries as a result of the existing challenges in the health care financing system stemming from 
uneven social and economic distribution such as low economic growth, huge variations in income level and poor 
infrastructure[1]. Developed countries like the United Kingdom, France and Germany have shown great interest 
in health insurance as a mechanism to collect and distribute resources for the health sector in a more equitable 
way [2]. Voluntary insurance mechanisms such as the Private Health Insurance (PHI) are implemented on a large 
scale in countries like Brazil, Chile, Namibia and South Africa [3] and community-based health insurance 
(CBHI) now available in developing countries like the Democratic Republic of the Congo, Ghana and Senegal 
[4].  
In Africa, CBHI provide quality healthcare and financial protection for citizens in terms of reducing 
their out-of-pocket payments [5]. In the past 25 years, several countries in Sub-Saharan Africa introduced a form 
of SHI. The major obstacle with SHI schemes in Africa was the limited number of enrolled people [6]. Therefore 
implementing a national health insurance which enrolls large number of people may be an ideal solution for 
African countries on their way to universal health coverage. Countries such as Rwanda [7] and Uganda [8] 
showed weak financial sustainability because of low renewal rates, high claims-to-revenue ratios and high 
operational costs. Presently, Ghana is the only country in sub-Saharan Africa that has successfully implemented a 
national health insurance scheme [6].  
The NHIS in Ghana is intended to provide financial risk protection against out- of- pocket health care 
expenditure for all Ghanaians. This is operational in over 145 districts across the country with a total cumulative 
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membership of over 18 million. Out of which over 8 million, representing 34% of Ghana’s current population are 
active card bearing members.The main sources of funding for the NHIS is the 2.5% National Health Insurance 
Levy (NHIL) on goods and services which forms 70% of the total revenue, social security taxes forms about 
23%, premium forms about 5% and other funds contributing 2% [9-10].  
The NHIS Medicines List in Ghana was developed in 2008 to serve as a guide to health providers in 
delivering healthcare services to subscribers. It contains medications in the various therapeutic groupings used in 
the management of about 95% disease conditions. The current list has five hundred and forty eight (548) 
formulations. The list excludes all anaesthetics (both local and general) and programme drugs [10]. Though 
drugs like Sulfadoxine + Pyrimethamine tablet, 525 mg, is a Programme drug, it has been maintained on the list 
due to its unavailability at some facilities across the country. This has been done to prevent malaria in pregnancy 
and aid the country’s attainment of the Millennium Development Goal 5 (which is to improve maternal health).  
In Ghana, most of the drugs on the National Health Insurance medicines list are generic. However, the 
perception and experiences of providers and clients on the NHIS medicines list is unknown since there has not 
been any published studies. Therefore, there was the need to determine the perception and experience of 
providers and clients in both public and private facilities on NHIS medicines list.  
 
2. Methods 
A descriptive cross-sectional study design was employed for the study. This study population was NHIS 
clienteles and workers at both KATH (Polyclinic Pharmacy) and Nimo Pharmacy as well as a management 
member from Bantama sub-metro office of NHIS. These two facilities were purposively selected because KATH 
was a teaching hospital attending to majority of the NHI clienteles and Nimo Pharmacy was one of the biggest 
and well patronized NHIS accredited private pharmacy shop in the sub- metro. A total sample size of 455 
comprising 420 clients and 20 health workers and 15 NHIS officials and administrators in both facilities .The 
sample was determined using Epi-Info software version 7 with an assumed expected frequency of 50% at 95% 
confidence interval plus a 10% non- response. In terms of distribution, 60% of the sampling size accessed KATH 
(Polyclinic Pharmacy) and 40% accessed Nimo Pharmacy. 
Systematic random sampling method was used to recruit participants. On average 20 participants were 
recruited in a day, using a recruitment interval of 2 and 3 for KATH and Nimo Pharmacy respectively starting 
with the arrival of the first client. This was repeated in both KATH and Nimo Pharmacy till a total sample size 
was attained. All NHIS clients (18 years and above) who took their prescriptions to both facilities during the 
survey were included in the study while NHIS clients under 18 years and those who did not bring their 
prescriptions to both facilities during the time of the survey were excluded from the study. A quantitative study 
was employed in which structured questionnaire was administered to providers and clients at both facilities. The 
data were analysed using descriptive and analytical approach with results expressed in frequencies, percentages 
and tables. Statistical significance for all testing was 0.05. Descriptive statistics variables were used to analyze 
the demographic variables of the participants while a chi-square test was used to determine differences in 
perception and experience on NHIS Medicines List among the clients and providers 
 
3. Results 
3.1 Demographic characteristics of respondents 
The age, gender, religion and occupation of the respondents have been presented. Majority of the clients who 
accessed NHIS from KATH (Polyclinic Pharmacy) and Nimo Pharmacy were within the age group of 31 – 40 
years (23.3%) and 21 – 30 years (20.7%) respectively, with overall mean age of 44 years and standard deviation 
of 15.2. Females were the predominant clients who accessed both facilities. Majority of them were traders 
(31.4%) and clients who accessed NHIS services from both facilities were mostly Christians (83.6%). Majority 
of providers at both KATH Polyclinic Pharmacy (55.0%) and Nimo Pharmacy (80.0%) were aged 21 – 30 years. 
The overall mean age of the provider was 30 years, with a standard deviation of 7.9. Also, 65% of the providers 
at KATH Polyclinic Pharmacy were males compared with 46.8% of them at Nimo Pharmacy. Majority of the 
providers from both facilities were Christians (KATH=100%; Nimo=93.3%), single (KATH=65.0%; 
Nimo=66.7%), and possessed a university degree (KATH=65.0%; Nimo=73.3%). Most of them (KATH=35.0%; 
Nimo=73.3%) also had working experience ranging from 0 – 5 years. 
Developing Country Studies                                                                                                                                                              www.iiste.org 
ISSN 2224-607X (Paper) ISSN 2225-0565 (Online) 
Vol.6, No.9, 2016 
 
59 
Table 1: Socio-demographic characteristics of Clients  
Variables Service Delivery Point   
KATH 
N = 252 (%) 
NIMO 
N = 168 (%) 
TOTAL X2( p-value) 
Age    7.24(0.299) 
≤ 20 3 (1.2) 2 (1.2) 5 (1.2)  
21 – 30 52 (20.6) 35 (20.8) 87 (20.7)  
31 – 40 66 (26.2) 32 (19.0) 98 (23.3)  
41 – 50  58 (23.0) 31 (18.5) 89 (21.2)  
51 – 60 38 (15.1) 34 (20.2) 72 (17.1)  
61 – 70 23 (9.1) 22 (13.1) 45 (10.7)  
70 + 12 (4.8) 12 (7.1) 24 (5.7)  
Mean = 44, SD = 15.2 Mean=43,SD=14.4 Mean=45,SD=16.1   
Gender    3.72(0.054) 
Male  86 (34.1) 73 (43.4) 159 (37.9)  
Female  166 (65.9) 95 (56.6) 261 (62.1)  
Religion    0.03(0.872) 
Christianity 210 (83.3) 141 (83.9) 351 (83.6)  
Islam 42 (16.7) 27 (16.1) 69 (16.4)  
Occupation     4.05(0.400) 
Trading  88 (34.9) 44 (26.2) 132 (31.4)  
Handiwork 14 (5.6) 9 (5.4) 23 (5.5)  
Agriculture  33 (13.1) 25 (14.9) 58 (13.8)  
Professional  50 (19.8) 35 (20.8) 85 (20.2)   
Unemployed  67 (26.6) 55 (32.7) 122 (29.1)  
Source: Author’s Field Data, 2015 
 
Table 2 Socio-demographic characteristics of Providers of NHIS medicines 
Variables Service Delivery Point   
KATH 
n = 20(%) 
NIMO 
n = 15(%) 
TOTAL X2(p-value) 
Age    6.67(0.036) 
21 – 30 11 (55.0) 12 (80.0) 23 (65.7)  
31 – 40  7 (35.0) 0 (0.0) 7 (20.0)  
41+ 2 (10.0) 3 (20.0) 5 (14.3)  
Mean = 30, SD = 7.9     
Gender    1.18(0.278) 
Male  13 (65.0) 7 (46.7) 20 (57.1)  
Female  7 (35.0) 8 (53.3) 15 (42.9)  
Religion    1.37(0.241) 
Christianity 20 (100.0) 14 (93.3) 34 (97.1)  
Islam 0 (0.0) 1 (6.7) 1 (2.9)  
Qualification    3.86(0.276) 
SHS 2 (10.0) 2 (13.3) 4 (11.4)  
HND 4 (20.0) 0 (0.0) 4 (11.4)  
Degree 13 (65.0) 11 (73.3) 24 (68.6)  
Masters 1 (5.0) 2 (13.3) 3 (8.6)  
Work experience (years)    5.19(0.158) 
0 – 5 7 (35.0) 11 (73.3) 18 (51.4)  
6 – 10 7 (35.0) 2 (13.3) 9 (25.7)  
11 – 20 4 (20.0) 1 (6.7) 5 (14.3)  
20 + 2 (10.0)  1(6.7) 3 (8.6)  
Source: Author’s Field Data, 2015 
 
3.2 Clients’ Perception and Experience about NHIS Medicines List  
Over seventy percent (74.2%) of the clients who accessed their NHIS medicines at KATH (Polyclinic Pharmacy) 
were aware that medicines prescribed to them were in their generics and only few ones were branded as 
compared with 81.6% of the clients at Nimo Pharmacy as shown in table 3. Whereas 60.3% of the clients who 
accessed KATH (Polyclinic Pharmacy) preferred both the generic and branded medicines, 52.4% of the clients 
Developing Country Studies                                                                                                                                                              www.iiste.org 
ISSN 2224-607X (Paper) ISSN 2225-0565 (Online) 
Vol.6, No.9, 2016 
 
60 
who accessed Nimo Pharmacy equally preferred both generic and branded medicines when given a choice. This 
was statistically not significant (p-value= 0.064). On opinion about the NHIS medicines list, majority of the 
clients who accessed both facilities found it to be effective (KATH=77.8%; Nimo=84.5%), available 
(KATH=67.9%; Nimo=89.9%), safe (KATH=97.2%; Nimo=96.4%) and with less side effects (KATH=98.8%; 
Nimo=94.6%). There was a statistically significant difference with respect to their opinion on NHIS medicines 
list in terms of cost (chi square = 39.81; p-value = 0.0001), availability (chi square = 27.33; p-value = 0.001) and 
side effect (chi square = 6.30; p-value = 0.012) as indicated in table 4.3. However respondent’s opinion on 
effectiveness (p-value = 0.088) and safety (p-value = 0.645) of the NHIS medicines list was not statistically 
significant. In response to the question whether people recover faster on NHIS medicines than the branded ones, 
almost an equal percentage from KATH (26.6%) and Nimo Pharmacy (26.2%) responded negatively. This was 
however statistically significant (p-value = 0.0001). 
Also, clients preference on medicines list either generics or branded would be based on 
recommendation from their doctors (KATH= 99.6%; Nimo= 98.81%), recommendation from their pharmacists 
(KATH= 51.59%; Nimo= 61.31%), how much money to save (KATH= 50.0%; Nimo= 17.86%) and severity of 
illness (KATH= 87.3%; Nimo= 81.55%) 
Table 3 Clients’ Perception and Experience on NHIS Medicines List  
Variable  Service Delivery Point  
TOTAL 
 
KATH 
n = 252 (%) 
NIMO 
n = 168 (%) 
X2 (p-value) 
 
Awareness of generic and branded 
as prescription medicines  
   
 
3.08 (0.079) 
Yes 187 (74.2) 137 (81.5) 324 (77.1)  
No   65 (25.8) 31 (18.5) 96 (22.9)  
Preference of medicine    5.49 (0.064) 
NHIS medicine/Generic 50 (19.8) 50 (29.8) 100 (23.8)  
Branded 50 (19.8) 30 (17.9) 80 (19.1)  
Both 152 (60.3) 88 (52.4) 240 (57.1)  
Opinion on NHIS medicines list     
Effectiveness     2.92 (0.088) 
 Effective 196 (77.8) 142 (84.5) 338 (80.5)  
 Ineffective  56 (22.2) 26 (15.5) 82 (19.5)  
Cost     39.81(0.001) 
 Expensive  7 (2.8) 37 (22.0) 44 (10.5)  
 Affordable  245 (97.2) 131 (78.0) 376 (89.5)  
Availability      27.33(0.001) 
 Available   171 (67.9) 151 (89.9) 322 (76.7)  
 Not available   81 (32.1) 17 (10.1) 98 (23.3)  
Safety      0.21 (0.645) 
 Safe  245 (97.2) 162 (96.4) 407 (96.9)  
 Unsafe  7(2.8) 6 (3.6) 13 (3.1)  
Side effects      6.30 (0.012) 
 More side effect 3 (1.2) 9 (5.4) 12 (2.9)  
 Less side effect  249 (98.8) 159 (94.6) 408 (97.1)  
Fast recovery when on NHIS 
medicines compared with branded 
ones 
   
 
41.44(0.001) 
Yes  35 (13.9) 67 (39.9) 102 (24.3)  
No  67 (26.6) 44 (26.2) 111 (26.4)  
Don’t know 150 (59.5) 57 (33.9) 207 (49.3)  
Preference when paying  
out-of-pocket 
   9.94(0.002) 
NHIS medicines 103 (40.9) 95 (56.6) 198 (47.1)  
Branded medicines 149 (59.1) 73 (43.4) 222 (52.9)  
Source: Author’s Field Data, 2015 
 
3.3 Providers’ Perception and Experience on NHIS Medicines List  
Majority of the providers from both facilities (KATH= 70.0%; Nimo= 66.7%) generally disagreed to the 
statement that ‘NHIS medicines or generics are more effective than branded ones’ as shown in table 4. About 
one-fourth (25.0%) of the providers at KATH (Polyclinic Pharmacy) disagreed to the statement that ‘NHIS 
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medicines were more available than the branded ones’ as compared with 13.3% of the providers at Nimo 
Pharmacy. Also, on the issue on whether ‘providers may substitute NHIS medicines for branded ones when 
NHIS medicines are out of stock’ and ‘NHIS medicines equivalent is not available on the market’, majority of 
the providers from both facilities (KATH= 40.0%; Nimo= 40.0%) disagreed with those statements. Also, seventy 
percent of the providers at KATH were uncertain about the quality of the NHIS medicines as compared with 
20.0% of providers at Nimo. Lastly, factors that can influence providers’ prescription pattern were assessed in 
terms of providers’ personal preference, clients’ personal preference, confidence in the generic company 
/manufacturer and advertisement by the generic company or manufacturer are detailed in table 4.   
Table 4 Providers’ Perception and Experience with NHIS Medicines List 
Statements   Strongly 
agree 
n (%) 
Agree 
 
n (%) 
Neutral  
 
n (%) 
Disagree 
 
n (%) 
Strongly 
disagree 
n (%) 
NHIS medicines or generics are more 
effective than branded ones 
KATH 0 (0.0) 2 (10.0) 1 (5.0) 14 (70.0) 3 (15.0) 
NIMO 1 (6.7) 3 (20.0) 1 (6.7) 10 (66.7) 0 (0.0) 
TOTAL  1 (2.9) 5 (14.3) 2 (5.7) 24 (68.6) 3 (8.6) 
NHIS medicines are available than the 
branded ones 
KATH 0 (0.0) 12 (60.0) 3 (15.0) 5 (25.0) 0 (0.0) 
NIMO 3 (20.0) 7 (46.7) 3 (20.0) 2 (13.3) 0 (0.0) 
TOTAL  3 (8.6)  19 (54.3) 6 (17.1) 7 (20.0) 0 (0.0) 
Providers may substitute NHIS 
medicines for branded ones when 
NHIS medicines are out of stock 
KATH 2 (10.0) 5 (25.0) 2 (10.0) 10 (50.0) 1 (5.0) 
NIMO 1 (6.7) 3 (20.0) 0 (0.0) 6 (40.0) 5 (33.3) 
TOTAL  3 (8.6) 8 (22.9) 2 (5.7) 16 (45.7) 6 (17.1) 
NHIS medicines equivalent is not 
available on the market  
KATH 0 (0.0) 4 (20.0) 6 (30.0) 8 (40.0) 2 (10.0) 
NIMO 2 (13.3) 3 (20.0) 1 (6.7) 6 (40.0) 3 (20.0) 
TOTAL  2 (5.7) 7 (20.0) 7 (20.0) 14 (40.0) 5 (14.3) 
Uncertain about the quality of the 
NHIS medicines 
KATH 0 (0.0) 14 (70.0) 1 (5.0) 4 (20.0) 1 (5.0) 
NIMO 3 (20.0) 3 (20.0) 5 (33.3) 4 (26.7) 0 (0.0) 
TOTAL  3 (8.6) 17 (48.6) 6 (17.1) 8 (22.9) 1 (2.9) 
Unsure about the bioequivalence of the 
generic and branded ones 
KATH 0 (0.0) 6 (30.0) 8 (40.0) 5 (25.0) 1 (5.0) 
NIMO 2 (13.7) 4 (26.7) 4 (26.7) 5 (33.3) 0 (0.0) 
TOTAL  2 (5.7) 10 (28.6) 12(34.3) 10 (28.6) 1 (2.9) 
Providers’ personal preference 
influence their prescribing behaviour   
KATH 1 (5.0) 11 (55.0) 5 (25.0) 3 (15.0) 0 (0.0) 
NIMO 6 (40.0) 2 (13.3) 3 (20.0) 3 (20.0) 1 (6.7) 
TOTAL  7 (20.0) 13 (37.1) 8 (22.9) 6 (17.1) 1 (2.9) 
Confidence in the generic 
company/manufacturer can influence 
providers’ prescription pattern 
KATH 2 (10.0) 15 (75.0) 2 (10.0) 1 (5.0) 0 (0.0) 
NIMO 4 (26.7) 9 (60.0) 0 (0.0) 2 (13.3) 0 (0.0) 
TOTAL  6 (17.1) 24 (68.6) 2 (5.7) 3 (8.6) 0 (0.0) 
Source: Author’s Field Data, 2015 
 
4. Discussion 
4.1 Clients’ Perception and Experience about NHIS Medicines List 
Generic medicines are used to effectively treat many of illnesses and this provides opportunity to substantially 
reduce costs to health sector and patients [11]. It was therefore encouraging to note that over seventy percent of 
the clients were aware of generic medicines and most of them (23.8%) preferred generics which were NHIS 
medicines to branded medicines (19.1%) as indicated in table 3. This might explain why significant proportions 
of clients (p-value= 0.001) were of the opinion that generic medicines or NHIS medicines were affordable 
(89.5%) as compared with branded medicines (See Table 3). Cost is one important factor considered by some 
clients and providers in considering generics or branded medicines [12]. As a result, a significant proportion of 
the clients (p-value=0.001) was of the opinion that NHIS medicines were less costly. This might further explain 
why majority of clients’ preferred generic medicines or NHIS medicines (23.8%) to branded medicines (19.1%). 
Contrary to the above, other studies consider efficacy as the most important factor in opting for either generics or 
branded medicines [13]. As a result, majority of clients were of the opinion that generic or NHIS medicines were 
effective, available and with less side effect and safety. This might explain why more of the clients would prefer 
NHIS medicines which were generics to branded medicines.  
Studies have found prescription to have a substantial effect on use of generic drugs, especially in 
developing countries where patients seek to buy exactly what is prescribed [14] and so, most clients accept 
substitution of generics for branded medicines based on their own recommendations to prescribers, 
recommendations by their doctors and by their pharmacists [15]. This explains why majority of the clients 
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indicated that their preference on medicines list either generics or branded would be based on recommendation 
from their doctors (KATH= 99.6%; NIMO= 98.81%), recommendation from their pharmacists (KATH= 51.59%; 
NIMO= 61.31%), how much money to save (KATH= 50.0%; Nimo= 17.86%) and severity of illness (KATH= 
87.3%; Nimo= 81.55%) This presupposes that the role of practitioners in promoting NHI medicines or branded 
medicines cannot be underestimated. As a result, clients might have received education on generics or NHIS 
medicines from their prescribers or practitioners and had understood the benefits associated with generics or 
NHIS medicines. This might explain why majority of clients would prefer NHIS medicines (23.8%) to branded 
medicines (19.1%) when paying out of their pocket as shown in Table 3. This is because clients or patients 
perceive generics as less expensive and also contain the same active ingredients as branded medicines [16]. 
 
4.2 Providers’ Perception and Experience on NHIS Medicines List 
Some providers raised major concerns regarding the effectiveness, availability, quality, safety, equivalence and 
bioequivalence on generic medicines and have acknowledged their economic benefits to the health care system 
[17-18]. This is evident in the study where majority of providers disagreed that NHI medicines or generic 
medicines were more effective than branded ones  
Some providers might refuse substitution of generics or NHIS medicines for branded ones as a result of 
substantial price difference between a generic and branded product [19] which may be as a result different 
packages, colours and shapes but with the same active ingredient and therefore would think it is a different 
medicine all together [20]. This explains why majority of providers were not sure about the bioequivalence of 
generic medicines and at the same time would not substitute NHI medicines for branded ones when out of stock 
because it might cause a problem when clients are asked to pay a difference or top-up.This also testifies why 
majority of the clients (78.8%) reported that insurance would not pay if one chose to take branded medicines  
 
5. Conclusion  
Majority of the clients were aware of NHI medicines or generics medicines and branded medicines. However, 
most of them preferred NHI medicines to branded medicines. The reasons provided for opting for NHI 
medicines were effective, affordable, available, safe and less side effects.  
Majority of providers disagreed that NHIS medicines or generic medicines are more effective than 
branded ones and might substitute NHIS medicines for branded ones when NHIS medicines are out of stock. 
Also, factors that might influence providers’ prescription patterns were stated as; provider’s personal preference, 
clients’ preference, confidence in the generic company and advertisement by generic company. 
 
6. Recommendation 
1. The Ministry of Health in collaboration with the NHIA should educate Ghanaians in order to increase 
awareness of NHIS medicines through the media. 
2. The NHIA should liaise with the Food and Drugs Authority and the Ghana Medical Association to 
educate physicians and pharmacists on effectiveness, bioequivalence of generic medicines so that they 
can provide the correct information to clients. 
3. A database of all generic medicines should be created as well as their inventory level for every 
accredited NHIS facility by the MOH and NHIA. This will make information on NHIS medicines list 
readily available and clients can easily be directed to another accredited pharmacy by the provider to 
access if they are not available at the visiting facility.  
4. Further research on providers’ opinion about the policies governing the NHIS medicines list can be 
carried out to help the NHIA address any concerns regarding the medicines list to enforce the 
sustainability of the scheme. 
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